This vial contains a lyophilized multi-peptide blend combining four investigational peptides:
BPC‑157 (Body Protection Compound-157) 10 mg
TB‑500 (Thymosin β4 fragment) 10 mg
GHK‑Cu (Copper-binding tripeptide) 50 mg
KPV (Lys-Pro-Val tripeptide) 10 mg
Packaged as a single vial in a freeze-dried, filler-free form, this blend is designed for laboratory research into tissue repair, regeneration, inflammation modulation, and extracellular-matrix dynamics. 
Intended Use
This product is supplied exclusively for in vitro and/or animal model research. It is not approved for human or veterinary therapeutic use and must be handled under appropriate laboratory protocols in compliance with institutional and regulatory guidelines.
Key Features & Specifications
Blend composition: BPC-157 10 mg + TB-500 10 mg + GHK-Cu 50 mg + KPV 10 mg (≈ 80 mg total lyophilized) BioLongevity Labs+1
Purity: > 99% (HPLC/MS certificate of analysis available) Polaris Peptides+1
Supplied as lyophilized powder; storage under dry conditions at ≤ -20 °C recommended until use, then after reconstitution store at 2-8 °C or per lab protocol. Polaris Peptides+1
Reconstitution: Use sterile water or appropriate buffer per your experimental design; avoid repeated freeze/thaw cycles.
Mechanism / Mode of Action (Research-Context)
The four peptides act via complementary but distinct pathways to support regeneration, angiogenesis, inflammation modulation and matrix remodeling:
BPC-157: Derived from a gastric protectant peptide, it has been shown in animal and cell studies to promote angiogenesis, fibroblast migration, epithelial and connective tissue repair, and modulate nitric oxide (NO) signaling. 
TB-500 (Thymosin β4 fragment): Promotes cell motility via actin-sequestration, enhances progenitor cell migration, angiogenesis and connective tissue repair. 
GHK-Cu: Naturally occurring copper-binding tripeptide (glycyl-histidyl-lysine-Cu), stimulates collagen and elastin synthesis, promotes wound healing, extracellular matrix remodeling, and acts in anti-oxidant/anti-inflammatory capacities. 
KPV: A short tripeptide fragment of α-MSH (Lys-Pro-Val) with demonstrated anti-inflammatory and immunomodulatory effects (e.g., reduction of NF-κB activation, cytokine release) in cell/animal models. 
When combined, this blend offers multifactorial research potential:
Angiogenesis & vascular formation (via TB-500/BPC-157/GHK-Cu)
Extracellular matrix & collagen deposition (GHK-Cu + BPC-157)
Regulation of inflammation (KPV + BPC-157 + GHK-Cu)
Tissue repair across skin, tendon/ligament, muscle, gastrointestinal and vascular models. 
Reported Research Findings & Possible Benefits (Research Context)
While human clinical data are extremely limited (and none of these peptides are approved therapies), pre-clinical and in-vitro findings indicate:
BPC-157 has shown accelerated wound healing, tendon/ligament repair, gut mucosal protection, and modulation of NO pathways. 
TB-500 has demonstrated increased endothelial cell migration, improved wound re-epithelialization, and enhanced repair in connective tissue models. 
GHK-Cu has been shown to stimulate collagen synthesis, increase expression of growth-factors (e.g., VEGF, bFGF), reduce oxidative stress and inflammation in fibroblasts and wound models. 
KPV has demonstrated anti-inflammatory effects in epithelial and immune cells, reducing pro-inflammatory cytokines and promoting healing in mucosal injury models. 
The synergy: Supplier research summaries indicate that combining these peptides may enhance outcomes of cell migration, collagen deposition, angiogenesis, and inflammatory modulation compared to single-agent models. 
Thus, for research purposes this blend may benefit investigations into:
Soft tissue repair (tendons, ligaments, muscles)
Wound healing and skin regeneration studies
Angiogenesis / vascularization models
Inflammation modulation, immune response in injury models
Extracellular matrix and collagen remodeling assays
Gastrointestinal mucosal injury / repair (via BPC-157 and KPV)
Important Considerations & Limitations
Not approved for human therapeutic use — All peptides in this blend are investigational. Researchers must ensure ethical/ regulatory compliance and appropriate oversight.
Limited human data: Most findings derive from animal or in-vitro research; extrapolation to human systems is speculative.
As potent bioactive peptides, careful handling, accurate dosing, sterility, and proper storage are required.
Because pathway activation (angiogenesis, collagen synthesis) may have implications in models of cancer or uncontrolled tissue growth, caution in design and interpretation is warranted. For example, BPC-157 has raised concerns in the context of angiogenesis.
For any in-vivo animal work, appropriate controls, dosing escalation, and safety monitoring must be built in.
Reconstitution, aliquoting, avoiding repeated freeze-thaw, and sterility are best practice.
Suggested Storage & Handling Protocol (Research Use Only)
Keep the lyophilized vial stored at ≤ -20 °C in a dry state until use.
Prior to reconstitution, allow the vial to equilibrate to room temperature for ~10 minutes to avoid condensation.
Reconstitute under sterile conditions using sterile water for injection or buffered saline according to your lab protocol (e.g., 1 mL to yield 80 mg/mL, then dilute as needed).
After reconstitution, aliquot into sterile vials to avoid repeated freeze-thaw cycles.
Store aliquots at 2-8 °C if used quickly, or ≤-20 °C for longer storage. Use within the timeframe validated in your lab (e.g., within 28 days).
Track lot number, certificate of analysis (purity), date of reconstitution, freeze-thaw history, and experimental conditions.
Summary
The KLOW Blend offers a high-purity, lyophilized peptide matrix combining BPC-157, TB-500, GHK-Cu and KPV — designed as a powerful research tool for investigators studying tissue repair, angiogenesis, inflammation, extracellular matrix biology and regeneration. With complementary mechanisms, the blend enables multi-pathway investigation of healing, regeneration and remodeling in vitro or in animal models. However, it is strictly for research use only and must be handled with full awareness of investigational status, limitations of current data, and rigorous lab practice.
Disclaimer: This description is for informational purposes only and not to be construed as a therapeutic or diagnostic claim. All use must comply with applicable laws, Institutional Animal Care and Use (IACUC) or equivalent protocols, and safety procedures.